Lifecode Inc., a Foster City, California-based next-generation-sequencing (NGS) based molecular diagnostics company, raised $20.5m in Series A funding round.
The round was led by Sequoia Capital, The Mayo Clinic, and Mayo Ventures.
Led by Chris Rivest, CEO, and Dr. Tim Triche, Laboratory Director, Lifecode is a specialized CLIA and CAP certified clinical laboratory focused on the genetic basis of human disease. With an initial focus on oncology, the company commits to improving patient care through actionable molecular information.
The company has received accreditation from the College of American Pathologists (CAP).